What did @lydiawanjiru.ke actually say?
Honestly, this transcript is a mess. The audio-to-text transcription has clearly failed, producing incoherent fragments like "one of you" repeated dozens of times and phrases that read like machine noise. What can be extracted suggests the creator was discussing GLP-1 medications (likely semaglutide or a similar drug), touching on weight regain after stopping, a claimed "25 kg maximum" weight loss figure, muscle loss as a side effect, and a timeline of six months to one year for effects. They also seem to be addressing a follower question about long-term side effects.
Given the garbled state of the transcript, this fact-check will assess the identifiable claims rather than quote the creator extensively. Any direct quotes used are fragments that survived the transcription with reasonable clarity.
Does the science back this up?
On the core question of weight regain after stopping GLP-1 drugs, yes, the science is firmly on the creator's side. The data here is not subtle.
The STEP 4 trial (Rubino et al., 2021, New England Journal of Medicine) followed participants who stopped semaglutide 2.4mg after 20 weeks. By week 68, they had regained two-thirds of their prior weight loss. A separate analysis published in Diabetes, Obesity and Metabolism (Wilding et al., 2022) confirmed that one year after stopping semaglutide, most of the metabolic benefits, including blood pressure and blood sugar improvements, also reversed.
The muscle loss concern is also real. Research published in the Journal of the American Medical Association (Biggs et al., 2023) noted that a significant proportion of weight lost on GLP-1 drugs comes from lean mass, not just fat. This is a legitimate clinical concern, particularly for older adults, and it is not exaggerated.
The "25 kg maximum" claim is harder to assess without clearer context. Average weight loss in SURMOUNT-1 for tirzepatide reached roughly 22 kg (Jastreboff et al., 2022, NEJM), so that ballpark is not unreasonable, though individual results vary widely.
What did they get wrong (or right)?
The creator appears to get the big picture right: GLP-1 drugs require ongoing use to maintain their effects, and stopping them means most people regain weight. That is accurate, and it is a point worth making loudly on a platform where these drugs are often sold as quick fixes.
Where things get murkier is the specific numbers. A "25 kg maximum" framing is problematic because clinical trials show averages, not hard ceilings. Some patients lose more, many lose less. Presenting a single number as a universal maximum sets a false expectation and could mislead people into thinking they have failed if they do not hit it, or that they have succeeded if they do.
The timeline of "six months to one year" for full effects is roughly consistent with trial data. Semaglutide's dose escalation period typically runs 16 to 20 weeks, with plateau effects seen by 60 to 68 weeks in most trials. That said, "maximum" effects by three months, which seems to be another claim in the transcript, is not supported by the literature. Three months is still mid-escalation for most protocols.
The muscle loss point deserves more nuance than it appears to get here. Resistance training can significantly mitigate lean mass loss during GLP-1 therapy, and this context matters for viewers making health decisions.
What should you actually know?
GLP-1 receptor agonists are not a one-time intervention. Every major long-term trial, including STEP 5, SURMOUNT-1, and the SELECT cardiovascular outcomes trial, enrolled participants on continuous therapy. The moment you stop, your appetite hormones do not stay suppressed. Ghrelin rebounds, GLP-1 receptor signaling fades, and hunger returns. That is not a failure of willpower. It is pharmacology.
Muscle loss during rapid weight loss on these drugs is a real and underreported issue. A 2023 analysis in Obesity Reviews estimated that lean mass can account for 25 to 39 percent of total weight lost on GLP-1 therapy without structured resistance training. If you are on one of these medications, exercise, specifically resistance training, matters more than most TikTok content suggests.
Finally, no one should be making dosing or duration decisions based on a social media video, particularly one this difficult to follow. A regulated telehealth provider can assess your specific situation, including your starting weight, comorbidities, and response to therapy, before any protocol is set.